BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
June 26, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., June 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Set to Join the Russell 2000® and Russell 3000® Indexes
June 23, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
June 21, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
May 16, 2023 16:05 ET
|
BioVie, Inc.
CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
April 20, 2023 08:30 ET
|
BioVie, Inc.
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
April 17, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
March 21, 2023 08:01 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Registration Details for "BioVie Day" Webinar
March 14, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
March 13, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 09, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...